How I treat lymphomas associated with HIV infection
10.3760/cma.j.cn121090-20241108-00441
- VernacularTitle:我如何治疗人类免疫缺陷病毒感染相关淋巴瘤
- Author:
Yao LIU
1
;
Chaoyu WANG
1
Author Information
1. 重庆大学附属肿瘤医院血液肿瘤中心，肿瘤转移与个体化诊治转化研究重庆市重点实验室，重庆 400030
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(2):120-125
- CountryChina
- Language:Chinese
-
Abstract:
The overall incidence of lymphomas associated with HIV infection is low, and only few hematological oncology specialties provide standardized treatment. Newly diagnosed patients with impaired immune function have a high incidence of complications, such as infections during induction chemotherapy, which increases treatment difficulties. For patients with relapse/refractory status, salvage treatment options are extremely limited, because new drug clinical trials are lacking. At present, both domestic and international clinical practices have shown that patients with lymphomas associated with HIV infection can achieve long-term survival after standardized combination antiretroviral therapy (cART) with targeted immunochemotherapy, followed by autologous hematopoietic stem cell transplantation (auto-HSCT) immediately after achieving complete remission. In recent years, some new drugs, such as XPO1 inhibitors, immune checkpoint inhibitors, antibody-drug conjugates (ADC drugs), bispecific antibodies, and small-molecule drugs, have been tentatively incorporated into treatment regimens for patients with lymphomas associated with HIV infection, and preliminary clinical data have been obtained. Based on two patients with lymphomas associated with HIV infection who were admitted to our center, this study proposed a standardized diagnostic and treatment pathway and provided corresponding references for clinicians to apply new drugs. The aim of this study was to promote diagnostic and treatment capabilities and improve the survival and quality of life of patients of lymphomas associated with HIV infection in China.
